Is ivonib/Tosuvo a targeted drug?

Ivosidenib (Ivosidenib) is indeed a targeted therapy drug, not a traditional chemotherapy drug. It targets IDH1 (isocitrate dehydrogenase type 1)—an enzyme that is mutated in some acute myeloid leukemia (AML)as well as some other tumors. IDH1 mutations can cause energy metabolism disorders and accumulation of abnormal metabolites in tumor cells, promoting tumor growth and drug resistance. Ivonib highly selectively inhibits the activity of mutant IDH1, blocks abnormal metabolic pathways, and fundamentally reduces tumor cell proliferation. It has a specific therapeutic effect on patients carrying susceptible mutations in this gene.

Different from traditional chemotherapy, targeted drugs emphasize "molecular targets + precise treatment". Therefore, the effect of ivonib on patients with IDH1 mutation-positive patients is more clear, and the toxic and side effects are relatively controllable. Overseas and Chinese registration studies have emphasized its positioning of “targeted, oral small molecule, precision treatment”.

In addition, as an oral small molecule targeted drug, ivonib has obvious advantages: compared with programs that require hospitalization for injection or long-term maintenance treatment, patients can take it in the outpatient department or at home, which is more convenient to manage and reduces interference with the body and life. The emergence of targeted drugs has brought new treatment options to patients with IDH1-mutated AML who have been treated mainly with chemotherapy in the past, with severe side effects and high recurrence rate. It also reflects the development direction of precision tumor treatment.

Therefore, it can be clearly said that ivonib is a "targeted drug", and its treatment logic is based on the identification and intervention of the molecular biological characteristics of tumors, rather than just cytotoxic killing. It represents a more precise and targeted treatment modality for patients with IDH1 mutations. A correct understanding of the properties and targets of drugs can help doctors formulate scientific, safe and effective individualized treatment plans for patients.

Reference: https://www.tibsovo.com/